已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Abstract 17067: Long-Term Transplant-Free Survival is Improved in Hypoplastic Left Heart Syndrome With Cell-Based Therapy

医学 左心发育不良综合征 诺伍德程序 外科 心脏移植 临床终点 心力衰竭 心室 移植 存活率 临床试验 内科学 随机对照试验 心脏病学 心脏病
作者
Sunjay Kaushal,Eric Naioti,Kevin Ramdas,Danial Mehranfard,Lisa McClain‐Moss,Michael Davis,Linda M. Lambert,Shaji C. Menon,Narutoshi Hibino,David L.S. Morales,Adil Husain,Kaitlyn Masih,Kristopher B. Deatrick,Sarah Speed,Anthony A. Oliva,Joshua M. Hare
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:148 (Suppl_1)
标识
DOI:10.1161/circ.148.suppl_1.17067
摘要

Hypoplastic left heart syndrome (HLHS) is a univentricular congenital heart defect that has high morbidity and mortality and requires three-stage surgical reconstruction so that the right ventricle (RV) delivers systemic circulation. Poor outcomes result from RV failure in the systemic position. Accordingly, we conducted a phase I clinical trial (called ELPIS) of Lomecel-B™, an allogeneic bone-marrow derived cell-based therapy designed to improve cardiovascular performance, delivered as a one-time treatment during the Stage II (Glenn) surgery at approximately 4 months after birth. This trial met its primary endpoint (safety through 1-year post-treatment). To assess whether Lomecel-B™ has survival benefits, all ELPIS patients ( n=10, 7 males, and 3 females) were enrolled in a multi-year follow-on study and compared to a retrospective control group which was identified by a relevant clinical HLHS database. Patients in both studies were assessed for up to 5 years (range 3.5 - 5.0 years post-treatment for ELPIS) for mortality, heart transplants, and stage III (Fontan) surgery. Outcomes were compared with long-term historical data from patients in the Single Ventricle Reconstruction (SVR) Trial receiving the same shunt type at Stage I (Norwood) operation. 5-year Kaplan-Meier survival was 100% in ELPIS patients with none requiring heart transplant. This compared to 81.6% (95% CI= [76.5, 87.0]) transplant-free survival in the SVR trial through 5 years post-Glenn surgery, and a 5.2% (95% CI= [2.0, 8.3]) heart transplantation rate (Figure 1). No stem cell related safety issues were reported. These findings support Lomecel-B™ as a potential adjunct to HLHS reconstruction surgery to improve clinical benefits and reduce the need for subsequent heart transplantation. Further long-term follow-up and controlled trials are both warranted and underway.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小小酥被卷了完成签到,获得积分10
刚刚
刚刚
chenchen发布了新的文献求助10
刚刚
2秒前
典雅的念梦完成签到,获得积分10
2秒前
3秒前
葫芦发布了新的文献求助10
3秒前
不困还能肝完成签到,获得积分10
4秒前
繁荣的琳完成签到,获得积分10
5秒前
PYF完成签到,获得积分10
5秒前
科研通AI6.3的应助被Jeff采纳,获得10
6秒前
lyw完成签到 ,获得积分10
7秒前
小新完成签到,获得积分10
7秒前
dpcrel发布了新的文献求助10
7秒前
yimo发布了新的文献求助100
7秒前
祈愿完成签到 ,获得积分10
8秒前
CAOHOU的应助被lmy采纳,获得10
8秒前
9秒前
Sunshine发布了新的文献求助10
9秒前
阿白完成签到,获得积分10
9秒前
上官若男的应助被橘子味采纳,获得10
10秒前
11秒前
12秒前
syvshc的应助被u290737采纳,获得10
12秒前
13秒前
13秒前
科研通AI6.3的应助被Jeff采纳,获得10
15秒前
科研通AI6.3的应助被Jeff采纳,获得10
15秒前
zhu发布了新的文献求助10
16秒前
yang1945发布了新的文献求助10
19秒前
19秒前
如梦完成签到 ,获得积分10
20秒前
前前前世完成签到,获得积分10
22秒前
曾曾曾曾完成签到 ,获得积分10
22秒前
所所的应助被默默雨灵采纳,获得10
22秒前
斯文败类的应助被浮云采纳,获得10
23秒前
dpcrel完成签到,获得积分10
23秒前
苏慕远完成签到 ,获得积分10
23秒前
打打的应助被蓝色卡车采纳,获得10
24秒前
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194810
求助须知:如何正确求助?哪些是违规求助? 9580544
关于积分的说明 21871741
捐赠科研通 7794414
什么是DOI,文献DOI怎么找? 3437768
关于科研通互助平台的介绍 2561095
邀请新用户注册赠送积分活动 2484480